Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Nano-bio material kills cancer cells, leaves healthy cells in unharmed

Scientists from the U.S. Department of Energy's (DOE) Argonne National Laboratory and the University of Chicago's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to soft biological material.

19 Aug 2009

U.S. FDA approval of miconazole MBT represents a significant milestone for Strativa Pharmaceuticals

Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad((R)) mucoadhesive buccal tablets (MBT) to treat oropharyngeal candidiasis (OPC).

19 Aug 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

BioDelivery Sciences International utilizes ICR's services for shareholder communications program

BioDelivery Sciences International, Inc. (BDSI®) (Nasdaq:BDSI) today announced that it has retained ICR, a leading investor relations and strategic advisory firm, to assist in the Company's shareholder communications program. ICR, founded in 1998 by a group of former institutional capital markets professionals, is headquartered in Westport, Connecticut, with offices in Westport, New York, Los Angeles, Boston, Chicago, Minneapolis, Beijing, and Shanghai.

19 Aug 2009

HealthHelp upgrades customer care technology with Qwest solutions

HealthHelp, a Houston-based radiology benefit-management company, recently upgraded its customer care technology with Qwest services. Now, physician offices can operate more efficiently with self-service, around-the-clock voice and data access to HealthHelp’s radiology benefit-management programs thanks to technology powered by Qwest Communications.

19 Aug 2009

Kolltan Pharmaceuticals raises additional $5 million to close Series A financing

Kolltan Pharmaceuticals, Inc. announced today that it has raised an additional $5 million to close its Series A preferred stock financing at $40 million. Participants in the Series A financing, originally announced in January 2009, include Purdue Pharma, L.P., HBM BioCapital L.P., the Pritzker/Vlock family, and other substantial private life science investors.

19 Aug 2009

Women air concerns on government takeover of health care

300,000 American women with breast cancer might have died over the last decade, if the US had adopted a British-style, government-run health care system. This shocking figure, from recent studies by the Lewin Group and Lancet Oncology, appears in a TV ad launched today by The Independent Women's Forum, a non-profit organization focused on issues of concern for women. The 60-second spot highlights the deadly risks to women under the "public option" - or co-op - plan currently under consideration in Congress.

19 Aug 2009

Fatigue during radiotherapy for breast or prostate cancer may be caused by inflammation

Patients who experience fatigue during radiotherapy for breast or prostate cancer may be reacting to activation of the proinflammatory cytokine network, a known inflammatory pathway, according to a report in Clinical Cancer Research, a journal of the American Association for Cancer Research.

19 Aug 2009

Low-dose estrogen effective for metastatic breast cancer

When estrogen-lowering drugs no longer control metastatic breast cancer, the opposite strategy might work. Raising estrogen levels benefited 30 percent of women whose metastatic breast cancer no longer responded to standard anti-estrogen treatment, according to research conducted at Washington University School of Medicine in St. Louis and collaborating institutions.

19 Aug 2009

SFDA approves China Pharma Holdings' generic Omeprazole Sodium injection

China Pharma Holdings, Inc., which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it has received approval from the Chinese State Food and Drug Administration ("SFDA) for the production of generic Omeprazole Sodium injections.

19 Aug 2009

Gloucester Pharma announces FDA Advisory Committee Meeting to discuss Romidepsin NDA

Gloucester Pharmaceuticals will discuss the New Drug Application for romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL) at the Oncologic Drugs Advisory Committee (ODAC) meeting on September 2, 2009.

18 Aug 2009

4SC starts phase 2 trial in hepatocellular carcinoma with 4SC-201 (resminostat)

4SC AG, the German drug discovery and development company, today announced the dosing of the first patient in its Phase II trial with 4SC-201 (resminostat), a pan-histone deacetylase (HDAC) inhibitor, as a new potential treatment option for patients with advanced hepatocellular carcinoma (HCC), the most frequent form of liver cancer.

18 Aug 2009

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

AEterna Zentaris Inc. today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

17 Aug 2009

Discovery of inherited gene variants that account for 37 percent of childhood acute lymphoblastic leukemia

Scientists at St. Jude Children’s Research Hospital have identified inherited variations in two genes that account for 37 percent of childhood acute lymphoblastic leukemia (ALL), including a gene that may help predict drug response.

16 Aug 2009

Obesity leads to worse prostate cancer in both black and whites equally

A new look at a large database of prostate cancer patients shows that obesity plays no favorites when it comes to increasing the risk of recurrence after surgery: Being way overweight is equally bad for blacks and whites, say researchers at Duke University Medical Center.

13 Aug 2009

First batch of cancer vaccine from Cancer Vaccine Collaborative goes into trial

The first batch of NY-ESO-1 recombinant protein produced in a facility supported entirely by non-profit entities has successfully cleared regulatory review and has entered clinical testing. The clinical trials are part of the Cancer Vaccine Collaborative, a joint program of the Cancer Research Institute, Inc. (CRI) and the Ludwig Institute for Cancer Research Ltd. (LICR).

13 Aug 2009

New tumour theory could change cancer treatment

University of Sydney researcher Dr Guy Lyons has come up with a new theory of cancer tumours that could change the way we treat cancer and conduct research into its causes.

13 Aug 2009

Wine may offer radioprotective effect for breast cancer patients

Drinking wine while undergoing radiation treatment for breast carcinoma may reduce the incidence of skin toxicity in breast cancer patients, according to a study in the August issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

13 Aug 2009

Discovery of compounds that selectively kills cancer stem cells

The cancer stem cells that drive tumor growth and resist chemotherapies and radiation treatments that kill other cancer cells aren't invincible after all. Researchers reporting online on August 13th in the journal Cell, a Cell Press publication, have discovered the first compound that targets those cancer stem cells directly.

13 Aug 2009

Researchers tackle aggressive cancer cells head on

A multi-institutional team of Boston-area researchers has discovered a chemical that works in mice to kill the rare but aggressive cells within breast cancers that have the ability to seed new tumors.

13 Aug 2009

Oncology News and Research

Further Reading

Nano-bio material kills cancer cells, leaves healthy cells in unharmed

U.S. FDA approval of miconazole MBT represents a significant milestone for Strativa Pharmaceuticals

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

BioDelivery Sciences International utilizes ICR's services for shareholder communications program

HealthHelp upgrades customer care technology with Qwest solutions

Kolltan Pharmaceuticals raises additional $5 million to close Series A financing

Women air concerns on government takeover of health care

Fatigue during radiotherapy for breast or prostate cancer may be caused by inflammation

Low-dose estrogen effective for metastatic breast cancer

SFDA approves China Pharma Holdings' generic Omeprazole Sodium injection

Gloucester Pharma announces FDA Advisory Committee Meeting to discuss Romidepsin NDA

4SC starts phase 2 trial in hepatocellular carcinoma with 4SC-201 (resminostat)

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

Discovery of inherited gene variants that account for 37 percent of childhood acute lymphoblastic leukemia

Obesity leads to worse prostate cancer in both black and whites equally

First batch of cancer vaccine from Cancer Vaccine Collaborative goes into trial

New tumour theory could change cancer treatment

Wine may offer radioprotective effect for breast cancer patients

Discovery of compounds that selectively kills cancer stem cells

Researchers tackle aggressive cancer cells head on

Cancer Research eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News